Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission
Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
Can a myeloma patient compare side effects for CAR-T vs. Bispecifics? Kind of, according to the video and research linked below.
You are an MM survivor. Perhaps you’ve enjoyed remissions following your induction therapy and your ASCT. But now you 2,3,4 chemo cocktails in and you are wondering about CAR-T and bispecific therapies.
Below are some key factors to consider for each therapy.
CAR-T vs Bispecifics: Which Myeloma Treatment Is Right for You?
“Compared to bispecific antibodies, CAR-T therapies are associated with substantially higher reporting odds of hematologic and inflammatory adverse events.”
In addition to the risk of short-term, long-term, and late-stage side effects, each MM patient must consider timing, cost, and efficacy.
“Background: CAR-T cell therapies and bispecific antibodies are novel immunotherapies for hematologic malignancies. While trials have reported immune-related toxicities, real-world comparative safety data remain limited. Identifying high-risk adverse events (AEs) in clinical practice is crucial for informed decision-making and patient safety.
Methods: This retrospective pharmacovigilance study analyzed U.S. FDA Adverse Event Reporting System (FAERS) data from 2022 to 2024. Reports involving CAR-T therapies and bispecific antibodies were extracted and categorized.
Descriptive statistics and disproportionality analyses using Reporting Odds Ratios (RORs) with 95% confidence intervals (CIs) were performed. Analyses were conducted in R version 4.5.0.
Results: A total of 3,867 AE reports were included, with 2,060 involving CAR-T therapies and 1,807 involving bispecific antibodies. CAR-T recipients had a higher mean age (60.4 years) compared to bispecific users (52.6 years), and males predominated in both groups.
Common AEs for CAR-T therapy included:
cytokine release syndrome (n = 697),
decreased neutrophil count (n = 355),
and decreased white blood cell count (n = 349).
For bispecific antibody users, frequently reported AEs included:
cytokine release syndrome (n = 339),
recurrent acute lymphocytic leukemia (n = 185),
and death (n = 176).
Disproportionality analysis revealed significantly elevated RORs for CAR-T therapies across a wide range of hematologic and inflammatory events. Notably, the ROR for
myelodysplastic syndrome was 25.7 (95% CI: 11.4–57.9),
hypophosphatemia 21.0 (8.4–52.8),
decreased immunoglobulin G 20.1 (7.4–54.4),
hypoalbuminemia 15.8 (7.0–35.8), and
elevated C-reactive protein 15.6 (7.2–33.7).
Additional elevated risks were observed for decreased lymphocyte count, peripheral edema, decreased appetite, acute myeloid leukemia, decreased platelet count, decreased neutrophil count, elevated gamma-glutamyltransferase, asthenia, decreased white blood cell count, hypocalcemia, disease progression, cough, hypokalemia, and elevated aspartate aminotransferase.
These results suggest that CAR-T therapies are associated with a broader and more severe toxicity profile than bispecific antibodies.
Conclusions: Compared to bispecific antibodies, CAR-T therapies are associated with substantially higher reporting odds of hematologic and inflammatory adverse events. The consistently elevated RORs across a wide range of toxicities underscore the need for rigorous monitoring and follow-up in patients receiving CAR-T therapy. These findings highlight the utility of FAERS-based pharmacovigilance in identifying post-marketing safety signals and informing clinical decision-making in immunotherapy.
side effects for CAR-T vs. Bispecifics side effects for CAR-T vs. Bispecifics side effects for CAR-T vs. Bispecifics
Leave a Comment:
2 comments
Steve romanelli says
3 weeks ago
David,thank you for all the information you provide,very helpful for those in need
